Although the carcinogenicity of Cr(VI) has been well documented by studies both in vitro and in vivo, its mechanism of action remains to be investigated. Our recent studies indicate that Cr(VI) induces HIF-11 activation. MAP kinase p38 and reactive oxygen species (ROS) are involved in this process. HIF-11 is a key regulatory protein for angiogenesis, which is a physiological process involving the growth of new blood vessels from pre-existing vessels. Solid tumors of smaller than 1 to 2 cubic millimeters are not vascularized. To spread, they need to be supplied by blood vessels that bring oxygen and nutrients and remove metabolic wastes. Inhibition of HIF-11 decreases cell transformation capacity in hypoxia and tumor growth in vivo, while overexpression of HIF-11 allows anchorage-independent growth in normoxia and development of more aggressive tumors. Since HIF-11 is important in cancer initiation and progression, it is likely that HIF-11 activation and angiogenesis could be important in Cr(VI)-mediated carcinogenesis. We hypothesize that ROS and HIF-11 activation play an important role in Cr(VI)-induced carcinogenesis. Human bronchial epithelial BEAS-2B cells and athymic female nude mice (3-4 weeks old) deficient in thymus-dependent (T-cell) immunological functions will be used in the present study.
Three specific aims are proposed.
Aim 1 will investigate the mechanism of Cr(VI)-induced ROS generation and the role of ROS in activation of HIF-11 and angiogenesis in vitro. The regulation of HIF-1 activity could occur at multiple levels: transcription, translation, and post-translational modifications. The questions remain open concerning at what level Cr(VI) induces HIF-11 activation.
Aim 2 will answer that question in cell system.
Aim 3 will investigate the roles of ROS and HIF-1 signaling in Cr(VI)-induced cell transformation in vitro, tumorigenesis, tumor growth, and metastasis in vivo. We anticipate that Cr(VI) induces angiogenesis via HIF-11 activation through ROS and MAP kinase p38, promoting Cr(VI)-induced cell transformation, tumorigenesis, tumor growth, and metastasis. .
Hexavalent chromium [Cr(VI)] is a known human carcinogen. The carcinogenicity of Cr(VI) has been well documented by studies both in vitro and in vivo. We hypothesize that Cr(VI) induces oxidative stress and activate HIF-1 angiogenesis signalling pathway, leading to cell transformation, tumorigenesis, tumor growth, and metastasis. The goal of this proposal is to test that hypothesis.
|Kim, Donghern; Dai, Jin; Park, Youn-Hee et al. (2016) Activation of Epidermal Growth Factor Receptor/p38/Hypoxia-inducible Factor-1Î± Is Pivotal for Angiogenesis and Tumorigenesis of Malignantly Transformed Cells Induced by Hexavalent Chromium. J Biol Chem 291:16271-81|
|Park, Youn-Hee; Kim, Donghern; Dai, Jin et al. (2015) Human bronchial epithelial BEAS-2B cells, an appropriate in vitro model to study heavy metals induced carcinogenesis. Toxicol Appl Pharmacol 287:240-5|
|Kim, Donghern; Dai, Jin; Fai, Leonard Yenwong et al. (2015) Constitutive activation of epidermal growth factor receptor promotes tumorigenesis of Cr(VI)-transformed cells through decreased reactive oxygen species and apoptosis resistance development. J Biol Chem 290:2213-24|
|Sun, Lijuan; Wang, Xin; Yao, Hua et al. (2012) Reactive oxygen species mediate Cr(VI)-induced S phase arrest through p53 in human colon cancer cells. J Environ Pathol Toxicol Oncol 31:95-107|